Two publications from the Institute of Pharmacology and Toxicology at Vetmeduni Vienna were awarded prizes. The article "STAT5 is a key regulator in NK cells and acts as molecular switch from tumor surveillance to tumor promotion", published in Cancer Discovery, received the research award from the City of Vienna Fund for innovative cancer research. The renowned Theodor Billroth Prize of the Vienna Medical Association was awarded to the publication "Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1 / 2 inhibitor therapy", published in Blood.
The City of Vienna Fund for Innovative Interdisciplinary Cancer Research is an initiative to support science and research in Vienna and to strengthen its importance in the public consciousness. This year's research funding award goes to a publication by first author Dagmar Gotthardt and last author Veronika Sexl from the Institute of Pharmacology and Toxicology at Vetmeduni Vienna. The research group showed for the first time that natural killer cells produce a factor (VEGF-A; Vascular Endothelial Growth Factor A) that can promote tumour growth. This study also defines STAT5 as a master regulator of NK-cell proliferation and lytic functions. Link to the publication can be found here.
The Theodor Billroth Prize of the Vienna Medical Association was awarded to another study led by Veronika Sexl, including first authors Edit Porpaczy (MedUni Vienna), Sabrina Tripolt and Andrea Hölbl-Kovacic (Vetmeduni Vienna). The results of this study show a risk for patients with the rare bone marrow disease myelofibrosis when treated with a JAK1/2 inhibitor, which is commonly used as a standard drug. Founded by the Vienna Chamber of Physicians, the Theodor Billroth Prize supports young academics and scientific activities. The Prize was awarded on December 17th 2018 in Vienna. Link to the publication can be found here.